Artelinic acid, a derivative of Artemisinin, is an antimalarial drug for the treatment of multidrug resistant strains of Plasmodium falciparum. Artelinic acid can be administered by various routes of administration, including intravenous, intramuscular and oral routes[1][2].

Artelinic acid (10 mg/kg; i.v.) has an elimination time t1/2 of 0.37 hours, a CL of 14.99 mL/min/kg, a Vss of 9.52 L and a AUC0-12h of 11219 ng h/mL for dogs[1]. Artelinic acid (10 mg/kg; intramuscular) has an elimination time t1/2 of 6.14 hours, a CL of 14.58 mL/min/kg, a Vss of 36.1 L and a AUC0-12h of 96372 ng h/mL for dogs[1].Artelinic acid (10 mg/kg; oral) has an elimination time t1/2 of 2.21 hours, a CL of 14.6 mL/min/kg, a Vss of 16.2 L and a AUC0-12h of 8839 ng h/mL for dogs[1]. Animal Model: Adult male beagle dogs 3-5 years old[1]

[1]. Li QG, et al. Pharmacology and toxicology of artelinic acid: preclinical investigations on pharmacokinetics, metabolism, protein and red blood cell binding, and acute and anorectic toxicities. Trans R Soc Trop Med Hyg. 1998 May-Jun;92(3):332-40. [2]. Hartell MG, et al. Nuclear magnetic resonance and molecular modeling analysis of the interaction of the antimalarial drugs artelinic acid and artesunic acid with beta-cyclodextrin. J Pharm Sci. 2004 Aug;93(8):2076-89.